Advances in liraglutide in the treatment of type 2 diabetes with nonalcoholic fatty liver disease

VernacularTitle:利拉鲁肽治疗2型糖尿病合并非酒精性脂肪性肝病的研究进展
Author: Haiping XIE ¹ ; Fan LIN ; Yan CHEN ; Ming ZHENG
Author Information

1. Provincial Clinical Medical College, Fujian Medical University, Fuzhou 350000, China
Publication Type:Research Article
Keywords: non-alcoholic fatty liver disease; diabetes mellitus, type 2; liraglutide
From: Journal of Clinical Hepatology 2020;36(9):2111-2114
CountryChina
Language:Chinese
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease, and its prevalence rate is increasing year by year. Insulin resistance and oxidative stress are the main pathogeneses of NAFLD, and there are still no effective drugs for the treatment of this disease. Insulin resistance is also a main pathogenesis of type 2 diabetes, and people with type 2 diabetes have a higher prevalence rate of NAFLD than those without diabetes. Liraglutide is a human glucagon-like peptide-1 analogue and can improve insulin resistance, and more and more studies have found that liraglutide has a certain therapeutic effect in patients with type 2 diabetes and NAFLD, while related mechanisms have not been fully clarified. This article reviews the therapeutic effect and related mechanisms of liraglutide in the treatment of type 2 diabetes and NAFLD.